672922-57-5

Basic information

• Product Name: Benzoic acid, 3-bromo-4-(methoxymethoxy)-, methyl ester
• CAS NO: 672922-57-5
• Molecular Formula: C10H11BrO4
• Molecular Weight: 275.099
• Mol File: 672922-57-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzoic acid, 3-bromo-4-(methoxymethoxy)-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-bromo-4-(methoxymethoxy)-, methyl ester(672922-57-5)
• EPA Substance Registry System: Benzoic acid, 3-bromo-4-(methoxymethoxy)-, methyl ester(672922-57-5)

Safety Data

• Hazardous Substances Data: 672922-57-5(Hazardous Substances Data)

Upstream product

• 99-96-7 4-hydroxy-benzoic acid 
• 109-87-5 Dimethoxymethane 
• 29415-97-2 methyl 3-bromo-4-hydroxybenzoate 
• 107-30-2 chloromethyl methyl ether 
• 99-76-3 methyl 4-hydroxylbenzoate 

Downstream Products

• 711012-11-2 (3-bromo-4-methoxymethoxy-benzyloxy)-tert-butyl-dimethyl-silane 
• 219565-74-9 3'-(2-propenyl)-5-propyl-(1,1'-biphenyl)-2,4'-diol 
• 35354-74-6 Honokiol 
• 672922-60-0 {4-Methoxymethoxy-3-[(E)-3-methyl-5-((4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-yl)-pent-2-enyl]-phenyl}-methanol 
• 672922-61-1 4-Methoxymethoxy-3-[(E)-3-methyl-5-((4aS,8aS)-2,5,5,8a-tetramethyl-3,4,4a,5,6,7,8,8a-octahydro-naphthalen-1-yl)-pent-2-enyl]-benzaldehyde 
• 672922-58-6 2-(3-bromo-4-methoxymethoxy-benzyloxy)-tetrahydro-pyran 
• 162269-91-2 (3-bromo-4-methoxymethoxy-phenyl)-methanol 

Relevant articles and documents

Template-Hopping Approach Leads to Potent, Selective, and Highly Soluble Bromo and Extraterminal Domain (BET) Second Bromodomain (BD2) Inhibitors

A number of reports have recently been published describing the discovery and optimization of bromo and extraterminal inhibitors which are selective for the second bromodomain (BD2); these include our own work toward GSK046 (3) and GSK620 (5). This paper describes our approach to mitigating the genotoxicity risk of GSK046 by replacement of the acetamide functionality with a heterocyclic ring. This was followed by a template-hopping and hybridization approach, guided by structure-based drug design, to incorporate learnings from other BD2-selective series, optimize the vector for the amide region, and explore the ZA cleft, leading to the identification of potent, selective, and bioavailable compounds 28 (GSK452), 39 (GSK737), and 36 (GSK217).

TRICYCLIC COMPOUND AND USE THEREOF

The present invention relates to: a compound selected from the group consisting of a tricyclic compound having the structure of formula I, a pharmaceutically acceptable salt, an isomer, a solvate and a precursor thereof; and a use thereof. The compound effectively controls GPR40, and thus, can be effectively used for the prophylaxis or treatment of diseases associated with GPR40, for example, diabetes and many other diseases.

Short and efficient synthesis of (+)-subersic acids

An efficient synthesis of (+)-subersic acid, the unnatural enantiomer, has been achieved from sclareol and p-hydroxybenzoic acid.